Vipox vector coding an HIV antigen and a cytokine

Details Vipox vector coding an HIV antigen and a cytokine Vipox vector coding an HIV antigen and a cytokine

2007-10-02

2007-10-02

Parkin, Jeffrey S. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Recombinant virus encoding one or more heterologous proteins...

C424S188100, C424S208100, C424S232100

Reexamination Certificate

active

09831307

ABSTRACT:
The invention relates to a fowl pox virus encoding an HIV antigen (gag and/or pol) and a cytokine (γ-interferon).

REFERENCES:
patent: 5766598 (1998-06-01), Paoletti et al.
patent: 5866136 (1999-02-01), Ramshaw et al.
Haynes, B. F., et al., 1996, “Update on the Issues of HIV Vaccine Development”, Ann. Med. 28:39-41.
Lee, T.-H., 1997, “Acquired Immunodeficiency Disease Vaccines: Design and Development”, inAIDS: Biology, Diagnosis, Treatment, and Prevention, fourth edition, DeVita, V. T., et al., eds.,Lippincott-Raven Publishers, Philadelphia, pp. 605-616.
Letvin, N. L., 1998, “Progress in the Development of an HIV-1 Vaccine”, Science 280:1875-1880.
Burton, D. R., and J. P. Moore, 1998, “Why do we not have an HIV vaccine and how can we make one?”, Nature Med. Vaccine Suppl. 4(5):495-498.
Johnston, M.I., 2000, “The Role of Nonhuman Primate Models in AIDS Vaccine Development”, Mol. Med. Today 6:267-270.
Feinberg, M. B., and J. P. Moore, 2002, “AIDS Vaccine Models: Challenging Challenge Viruses”, Nature Med. 8(3):207-210.
Fatkenheuer, G., Thiesen, A., Rockstroh J., et al., “Virological Treatment Failure of Protease Inhibitor Therapy in an Unselected Cohort of HIV-Infected Patients”,Aids(11):F-113-116 (1997).
Finzi, D., Hermankova, M., Pierson, T., et al., “Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy”,Science278:1295-1300 (1997).
Ogg, G.S., Jin, X., Bonhoeffer, S., et al., “Quantitation of HIV-1 Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA”,Science279:2103-2105 (1998).
Tsoukas, C.M., Raboud, J., Bernard, N.F., et al., “Active Immunization of Patients with HIV Infection: A Study of the Effect of VaxSyn, a Recombinant HIV Envelope Subunit Vaccine, on Progression of Immunodeficiency”,AIDS Res Hum Restroviruses14:483-490 (1998).
Eron, J.J. Jr., Ashby, M.A., Giordano, M.F., et al., “Randomised Trial of MNrgp120 HIV-1 Vaccine in Sympomless HIV-1 Infection”,Lancet348:1547-1551 (1996).
Veenstra, J., Williams, I.G., Colebunders, R., et al., “Immunization with Recombinant p. 17/p. 24:Ty Virus-like Particles in Human Immunodeficiency Virus-Infected Persons”,J Infect Dis174:862-866 (1996).
Rosenberg, E.S., Billingsley, J.M., Caliendo, A.M., et al., “Vigorous HIV-1 Specific CD4+T Cell Responses Associated with Control of Viremia”,Science278:1447-1450 (1997).
Agy, M.B., Frumkin, L.R., Corey, L., et al., “Infection ofMacaca nemestrinaby Human Immunodeficiency Virus Type -1”,Science257:103-106 (1992).
Kent, S. J., Woodward, A., Zhao, A. “Human Immunodeficiency Virus Type 1 (HIV-1) Specific T Cell Responses Correlate with Control of Acute HIV-1 Infection in Macaques”,J Infect Dis176:1188-1197 (1997).
Kent, S.J., Zhao, A., Best, S., Chandler, J.D., Boyle, D.B., Ramshaw I.A., “Enhanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus”,J Virol72:10180-10188 (1998).
Cardinal, B., Kent, S.J.,Lab, “Behavioral Effects of Simple Manipulable Environmental Enrichment on Pair-housed Juvenile Macaques”,Primate Newsletter(1997).
Andrew, M.E., Boyle, D.B., Coupar, B.E., Whitfield, P.L., Both, G.W., Bellamy, A.R., “Vaccina Virus Recombinants Expressing the SA11 Rotavirus VP7 Glycoprotein Gene Induce Serotype-Specific Neutralizing Antibodies”,J Virol61:1054-1060 (1987).
Gray, P., Leung, D., Pennica, D., et al., “Expression of Human Immune Interferon cDNA inE. coliand Monkey Cells”,Nature295:503-508 (1982).
Heine, H.G., Boyle, D.B., “Infectious Bursal Disease Virus Structural Protein VP 2 Expressed by a Fowlpox Virus Recombinant Confers Protection Against Disease in Chickens”,Arch Virol131:277-292 (1993).
Boyle, D.B., Coupar, B.E., “A Dominant Selectable Marker for the Construction of Recombinant Poxviruses”,Gene65:123-128 (1988).
De St. Groth, F., “The Evaluation of Limiting Dilution Assays”,J Immunol Methods49:R11-23 (1982).

Affiliated with

Also associated with

Rating

Vipox vector coding an HIV antigen and a cytokine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vipox vector coding an HIV antigen and a cytokine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vipox vector coding an HIV antigen and a cytokine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3843761